Dr. Halpern is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-288-1000Fax+1 206-606-1025
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2013 - 2016
University of ChicagoResidency, Internal Medicine, 2009 - 2012
The Warren Alpert Medical School of Brown UniversityClass of 2009
Certifications & Licensure
WA State Medical License 2013 - 2026
IL State Medical License 2009 - 2014- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2016 Dec 01
- Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm Start of enrollment: 2016 Dec 30
- A Study of Oral TP-3654 in Patients With Myelofibrosis Start of enrollment: 2019 Dec 16
Roles: Contact
Publications & Presentations
PubMed
- 58 citationsAge-related differences in disease characteristics and clinical outcomes in polycythemia veraBrady L. Stein, Santosh L. Saraf, Urszula A. Sobol, Anna B. Halpern, Jamile M. Shammo
Leukemia & Lymphoma. 2013-01-08 - 300 citationsAllogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?Daisuke Araki, Brent L. Wood, Megan Othus, Jerald P. Radich, Anna B. Halpern
Journal of Clinical Oncology. 2016-09-19 - 10 citationsEarly hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.Anna B. Halpern, Nicholas P Howard, Megan Othus, Paul C. Hendrie, Nikita V Baclig
Leukemia. 2020-02-01
Journal Articles
- Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
Abstracts/Posters
- Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community SettingAnna B. Halpern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...Anna B. Halpern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myel...Anna B. Halpern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Othe...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Sorafenib plus GCLAM Held Safe in AML, MDS Phase-1 StudyApril 22nd, 2019
iHealthHome Supports Cancer Researchers on Home Telemonitoring Study of Leukemia PatientsDecember 1st, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
